Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history.

This study represents a secondary analysis of a double-blind, placebo-controlled, event-driven, phase 3b randomized clinical trial. The trial was conducted across 444 centers in 33 countries, enrolling a total of 9,650 participants. The study population consisted of individuals with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease. Participants were stratified at baseline according to the presence or absence of a history of heart failure. The intervention involved administering once-daily oral semaglutide in addition to standard of care, while the comparator group received placebo in addition to standard of care. The follow-up duration for the study was 47.5 months, with a standard deviation of 10.9 months.

The primary outcome measure was a prespecified composite heart failure outcome, defined as the time to the first occurrence of heart failure hospitalization, urgent heart failure visit, or cardiovascular death. Results were analyzed separately for participants with and without a history of heart failure at baseline. In the subgroup of participants with heart failure at baseline, the use of oral semaglutide was associated with a hazard ratio of 0.78 for the composite heart failure outcome. The 95% confidence interval for this estimate ranged from 0.63 to 0.96, with a p-value indicating statistical significance for this reduction. Conversely, in participants without heart failure at baseline, the hazard ratio was 1.01, with a 95% confidence interval of 0.84 to 1.20, indicating no statistically significant effect on the primary outcome in this group.

Further stratification by ejection fraction provided additional detail on the primary outcome. Among participants with heart failure and preserved ejection fraction, oral semaglutide demonstrated a hazard ratio of 0.59, with a 95% confidence interval of 0.39 to 0.86, suggesting a reduction in the composite outcome. In contrast, for participants with heart failure and reduced ejection fraction, the hazard ratio was 0.98, with a 95% confidence interval of 0.70 to 1.38, showing no significant effect. Regarding the secondary outcome of major adverse cardiovascular events (MACE), the hazard ratio was 0.83 for participants with heart failure history, with a 95% confidence interval of 0.68 to 1.01. For participants without heart failure history, the MACE hazard ratio was 0.86, with a 95% confidence interval of 0.75 to 0.98, indicating a reduction in this secondary endpoint.

Safety and tolerability findings indicated that the occurrence of serious adverse events was similar between the oral semaglutide group and the placebo group. Specifically, 594 participants, representing 53.8% of the cohort, experienced serious adverse events while on oral semaglutide. The specific rates of adverse events were not reported in the available data. This observation suggests that the safety profile regarding serious adverse events did not differ significantly from placebo in this large population.

When comparing these results to prior landmark studies in the therapeutic area of heart failure and type 2 diabetes, the distinction between patients with and without baseline heart failure is notable. Previous data often focused on broader cardiovascular mortality and non-fatal events, whereas this analysis highlights a specific signal in the heart failure subgroup. The lack of effect in patients without baseline heart failure suggests that the mechanism of benefit may be specific to those with existing heart failure pathology. This contrasts with some broader cardiovascular outcome trials where benefits were observed across the entire population regardless of heart failure status.

Key methodological limitations include the observational nature of the secondary analysis, which precludes definitive causal language regarding the drug's effect. The stratification by baseline heart failure status creates two distinct populations, and the results must be interpreted within the context of the overall trial design. Potential biases inherent in secondary analyses, such as multiple testing issues, may influence the precision of the subgroup estimates. Additionally, the lack of reported specific adverse event rates limits the ability to fully assess tolerability beyond the serious adverse event comparison.

Clinically, these results imply that oral semaglutide may offer a specific benefit in reducing heart failure hospitalizations, urgent visits, or cardiovascular death for patients with type 2 diabetes who already have a history of heart failure. For patients without baseline heart failure, the data does not support a reduction in the composite heart failure outcome, although a reduction in MACE was observed. Practitioners should consider these findings when evaluating treatment options for patients with type 2 diabetes and comorbid heart failure. However, the absence of effect in the non-heart failure subgroup warrants caution in extrapolating these results to all patients with type 2 diabetes and cardiovascular risk.

Several questions remain unanswered. The long-term durability of the observed benefit in the heart failure subgroup requires further investigation. The reasons for the lack of effect in patients with reduced ejection fraction versus preserved ejection fraction need clarification, as the data showed no effect in the reduced ejection fraction group. Furthermore, the specific mechanisms driving the reduction in heart failure events versus the reduction in MACE in the non-heart failure population are not elucidated by this study. Future research should aim to define the optimal patient population for oral semaglutide therapy in the context of heart failure risk.